EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Vitro Biopharma's Enterprise Value is $0.00 Mil.
Vitro Biopharma's Free Cash Flow for the trailing twelve months (TTM) ended in Oct. 2022 was $-2.53 Mil. Therefore, Vitro Biopharma's EV-to-FCF for today is 0.00.
The historical rank and industry rank for Vitro Biopharma's EV-to-FCF or its related term are showing as below:
VTRO'
s EV-to-FCF Range Over the Past 10 Years
Min: -44.5 Med: -14.75 Max: -5.78
Current: -4.14
During the past 13 years, the highest EV-to-FCF of Vitro Biopharma was -5.78. The lowest was -44.50. And the median was -14.75.
VTRO's EV-to-FCF is not ranked
in the Biotechnology industry.
Industry Median: 16.69
vs VTRO: -4.14
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vitro Biopharma's PE Ratio (TTM) for today is calculated as:
Vitro Biopharma's share price for today is $0.00.
Vitro Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Oct. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Vitro Biopharma EV-to-FCF Related Terms
Vitro Biopharma EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Vitro Biopharma's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vitro Biopharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitro Biopharma EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vitro Biopharma's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Vitro Biopharma's EV-to-FCF falls into.
Vitro Biopharma's current Enterprise Value is $0.00 Mil.
Vitro Biopharma's Free Cash Flow for the trailing twelve months (TTM) ended in Oct. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.53 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vitro Biopharma (VTRO) has a EV-to-FCF of 0.00 as of Jul. 09, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Vitro Biopharma and its competitors.
Is Vitro Biopharma's EV-to-FCF too high?
Vitro Biopharma's current EV-to-FCF is 0.00.
How does Vitro Biopharma's EV-to-FCF compare to ?
Vitro Biopharma's EV-to-FCF of 0.00 can be compared against companies in the Biotechnology industry. The industry median EV-to-FCF is 16.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.69, based on 327 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Vitro Biopharma and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitro Biopharma's current EV-to-FCF is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitro Biopharma stock overvalued right now?
Vitro Biopharma (VTRO) has a current EV-to-FCF of 0.00. The current EV-to-FCF is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Vitro Biopharma (VTRO), the current EV-to-FCF is 0.00 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vitro Diagnostics Inc is a US-based company, which is dedicated to providing high-quality commercialized cell lines, media, and stem cell technology for applications in stem cell research, drug discovery, and therapies. In addition, it also provides tools for clinical development focused on Mesenchymal Stem Cells (MSCs). Further, it offers cancer-associated fibroblasts (CAFs), which are used in the discovery of a new type of CAFs present in pancreatic cancer tumors, called pancreatic stellate cells. Geographically business activities are functioned through the region of United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VTRO has been successfully added to your 